Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases

Andreas Pinter; Dagmar Wilsmann-Theis; Wiebke K Peitsch; Rotraut Mössner

doi:10.1111/1346-8138.14815

Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases

J Dermatol. 2019 May;46(5):426-430. doi: 10.1111/1346-8138.14815. Epub 2019 Feb 20.

Authors

Andreas Pinter¹, Dagmar Wilsmann-Theis², Wiebke K Peitsch³, Rotraut Mössner⁴

Affiliations

¹ Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
² Department for Dermatology and Allergy, University Bonn, Bonn, Germany.
³ Department of Dermatology and Phlebology, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
⁴ Department of Dermatology, Venereology and Allergology, University Clinic Göttingen, Göttingen, Germany.

PMID: 30786053
DOI: 10.1111/1346-8138.14815

Abstract

Palmoplantar pustular psoriasis, also termed palmoplantar pustulosis (PPP), is a rare disease affecting the palmoplantar regions characterized by sterile, yellow to brown pustules mostly on erythematous skin. PPP is related to a high burden due to painful, impaired and stigmatizing character. Several isoforms of interleukin (IL) have been implicated in its pathophysiology. Here, we report on four patients with PPP treated with the novel IL-17 receptor A blocker brodalumab, in whom this therapy was not successful or showed moderate improvement combined with adverse events.

Keywords: palmoplantar pustular psoriasis; brodalumab; interleukin-17 A; interleukin-17 receptor A; pustulosis palmoplantaris.

Publication types

Case Reports

MeSH terms

Adult
Aged
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Dermatologic Agents / administration & dosage
Dermatologic Agents / adverse effects*
Disease Progression
Drug Therapy, Combination / adverse effects
Drug Therapy, Combination / methods
Female
Humans
Middle Aged
Mometasone Furoate / therapeutic use
Psoriasis / diagnosis
Psoriasis / drug therapy*
Psoriasis / immunology
Psoriasis / pathology
Receptors, Interleukin-17 / antagonists & inhibitors*
Receptors, Interleukin-17 / immunology
Recurrence
Severity of Illness Index
Treatment Outcome
Withholding Treatment

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatologic Agents
IL17RA protein, human
Receptors, Interleukin-17
Mometasone Furoate
brodalumab